PDCD1 and colitis: Data from metanalyses indicate that in case of ipilimumab-treatment the most frequent cause of death is colitis (approx. 70%), while targeting the PD-1/PD-L1 axis is most frequently associated with fatal pneumonitis (approx. 35%), hepatitis (approx. 20%) and neurotoxicity (approx. 15%).